Independent
Tenure on this board
1.4 yrs
Also a director at
Si-bone Inc (SIBN)
Meeting calendar
BRKR · Annual meeting · Thursday, May 21, 2026
Bruker Corp
3 nominees · 3 ballot items.
Elect three Class II directors; advisory vote to approve 2025 named executive officer compensation (Say-on-Pay); ratify PricewaterhouseCoopers LLP as independent auditor for 2026.
Market cap
$8.9B
1Y TSR
+42.7%
Board grade
B-
Record date
Apr 1, 2026
Filing
DEF 14A
Meeting concluded · May 21, 2026
Follow how the vote landed and what changed on Bruker Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect Laura A. Francis, John J. (Jack) Phillips, and Hermann F. Requardt, Ph.D. as Class II directors for three-year terms expiring in 2029.
- 2
Advisory Vote on the 2025 Compensation of Named Executive Officers (Say-on-Pay
ManagementBoard: FORNon-binding, advisory vote to approve the 2025 compensation of the named executive officers as disclosed in the proxy statement.
More detail
The board is asking shareholders to cast a non-binding advisory vote to approve the company’s 2025 named executive officer compensation as disclosed in the proxy, reflecting the Compensation Discussion and Analysis, compensation tables and narratives. Management seeks this advisory endorsement to validate its compensation philosophy of pay-for-performance, retention and alignment with long-term shareholder value, and to demonstrate responsiveness to shareholder governance norms (Dodd-Frank say-on-pay). The CD&A describes target cash incentives, long-term equity awards (mix of stock options and RSUs), metrics (currency-adjusted revenue growth, non-GAAP gross profit or operating profit, working capital improvement, non-GAAP EPS), and individual performance components. The board recommends a vote FOR, arguing that compensation decisions are tied to financial and individual performance, include governance safeguards (clawback policy, stock ownership guidelines, independent compensation consultant), and that prior say-on-pay support (~95% in 2025) affirms shareholder alignment. The vote is advisory and non-binding, but the board and Compensation Committee will consider results when making future decisions. Given the company’s recent performance headwinds (organic revenue decline, lower non-GAAP EPS), shareholders may weigh whether realized payouts and incentive targets appropriately reflected performance and whether the mix of option-based awards and RSUs aligns pay with long-term shareholder returns; management highlights governance controls and rationale for the compensation mix.
- 3
Ratification of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of PricewaterhouseCoopers LLP as Bruker’s independent registered public accounting firm for fiscal year 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
0.5 yrs
Independent
Tenure on this board
10.9 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Orbis Allan Gray Ltd | 11.1% | 16,852,868 | $609M |
| 2 | Pallas Capital Advisors LLC | 6.2% | 9,481,821 | $342M |
| 3 | FMR LLC | 5.5% | 8,435,928 | $305M |
| 4 | BlackRock, Inc. | 4.3% | 6,513,844 | $235M |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.2% | 4,855,915 | $175M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 4,817,076 | $174M |
| 7 | FMR LLC | 3.1% | 4,767,402 | $172M |
| 8 | STATE STREET CORP | 2.6% | 3,908,693 | $141M |
| 9 | EDMOND DE ROTHSCHILD HOLDING S.A. | 2.2% | 3,356,850 | $121M |
| 10 | Sculptor Capital LP | 2.1% | 3,270,000 | $118M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Bruker Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.7B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Reference
Frequently asked questions
- When is the Bruker Corp 2026 annual meeting?
- Bruker Corp (BRKR) holds its 2026 annual shareholder meeting on Thursday, May 21, 2026.
- What is the record date for the Bruker Corp 2026 meeting?
- The record date for the Bruker Corp 2026 meeting is Wednesday, April 1, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Bruker Corp's 2026 meeting?
- The board is presenting 3 director nominees at the Bruker Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Bruker Corp 2026 meeting?
- Shareholders will vote on 3 proposals at the Bruker Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.